The content is available as a PDF (433.9 KB).
letter . 2021 May 8:jiab248. doi: 10.1093/infdis/jiab248
Prolonged COVID-19 Disease in a Patient with Rheumatoid Arthritis on Rituximab Therapy
Rachel Aviv
1,#,✉, Andrew Weber
1,#,✉, Tarif Anzum
2, Matthew Federbush
2, Diane Horowitz
3,4, Effie Singas
1,4
Rachel Aviv
1Division of Pulmonary, Critical Care, and Sleep Medicine. Department of Medicine. Northwell Health. New York, USA
Find articles by Rachel Aviv
Andrew Weber
1Division of Pulmonary, Critical Care, and Sleep Medicine. Department of Medicine. Northwell Health. New York, USA
Find articles by Andrew Weber
Matthew Federbush
2Department of Medicine. Northwell Health. New York, USA
Find articles by Matthew Federbush
Diane Horowitz
3Division of Rheumatology, Department of Medicine. Northwell Health. New York, USA
4Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Hofstra University Hempstead, NY
Find articles by Diane Horowitz
Effie Singas
1Division of Pulmonary, Critical Care, and Sleep Medicine. Department of Medicine. Northwell Health. New York, USA
4Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Hofstra University Hempstead, NY
Find articles by Effie Singas
1Division of Pulmonary, Critical Care, and Sleep Medicine. Department of Medicine. Northwell Health. New York, USA
2Department of Medicine. Northwell Health. New York, USA
3Division of Rheumatology, Department of Medicine. Northwell Health. New York, USA
4Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Hofstra University Hempstead, NY
#
Both Authors contributed equally to this manuscript.
✉
Corresponding Author(s): Rachel Aviv (raviv@northwell.edu), 410 Lakeville Road. Suite 107. Lake Success, NY 11040, Office Phone: 516-465-5400; Fax: 516-465-5422
✉
Corresponding Author(s): Andrew Weber (aweber4@northwell.edu), 410 Lakeville Road. Suite 107. Lake Success, NY 11040, Office Phone: 516-465-5400; Fax: 516-465-5422
Received 2021 Mar 30.
Keywords: Prolonged COVID-19, SARS-CoV-2, COVID-19, Rituximab, Convalescent Plasma, Immunosuppression, B-Cell Depletion, Remdesivir
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
PMCID: PMC8135965 PMID: 33964153
See "Response to Aviv et al", jiab249.